Segall Bryant & Hamill LLC Trims Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Segall Bryant & Hamill LLC lessened its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 12.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 306,352 shares of the biotechnology company's stock after selling 44,987 shares during the period. Segall Bryant & Hamill LLC owned about 0.13% of ADMA Biologics worth $5,254,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp increased its stake in ADMA Biologics by 61.4% during the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company's stock worth $259,970,000 after buying an additional 4,945,063 shares during the period. Perpetual Ltd acquired a new position in shares of ADMA Biologics in the fourth quarter worth $62,300,000. Lord Abbett & CO. LLC purchased a new stake in shares of ADMA Biologics during the third quarter worth $61,858,000. Allspring Global Investments Holdings LLC raised its stake in shares of ADMA Biologics by 1,144.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock valued at $51,016,000 after acquiring an additional 2,613,482 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in ADMA Biologics in the fourth quarter valued at $19,076,000. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Down 2.1 %

Shares of ADMA stock traded down $0.42 on Tuesday, reaching $19.42. 2,224,361 shares of the stock were exchanged, compared to its average volume of 3,521,414. The company has a market capitalization of $4.59 billion, a price-to-earnings ratio of 69.36 and a beta of 0.60. The business's 50 day moving average price is $17.27 and its 200 day moving average price is $18.18. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a twelve month low of $5.90 and a twelve month high of $23.64.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.